Tag: ADC resistance
-
Why Some Breast Cancers Resist Antibody Drug Conjugates (ADCs)
Unraveling Resistance to Antibody Drug Conjugates in Breast Cancer Antibody drug conjugates (ADCs) represent a promising class of targeted cancer therapies that couple a tumor-homing antibody with a potent cytotoxic payload. In breast cancer, this approach aims to deliver chemotherapy directly to malignant cells while sparing most healthy tissue. Yet, not all patients respond, and…
-
New Insights into Why Some Breast Cancers Resist Antibody-Drug Conjugates (ADCs) Therapy
Understanding ADCs and Why They Matter in Breast Cancer Antibody‑drug conjugates (ADCs) are a cutting‑edge class of cancer therapies designed to target malignant cells with precision. By pairing a cancer‑specific antibody with a potent cytotoxic drug, ADCs aim to destroy tumor cells while limiting damage to healthy tissue. In breast cancer, ADCs have shown promise,…
-
Why Some Breast Cancers Resist Antibody Drug Conjugates: New Mayo Clinic Insights
Understanding the Challenge: Breast Cancer and Antibody Drug Conjugates Antibody drug conjugates (ADCs) represent a promising class of targeted cancer therapies. They couple a cancer-seeking antibody with a potent cytotoxic drug, delivering treatment directly to tumor cells while aiming to spare healthy tissue. In breast cancer, these therapies have shown notable potential, especially for tumors…